Why Impact BioMedical Inc.’s (IBO) Stock Is Up 5.35%
As of Tuesday, September 15, Impact BioMedical Inc.’s IBO share price has surged by 5.35%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc.
Commentary & Analysis
Why Impact BioMedical Inc.’s (IBO) Stock Is Up 11.57%
As of Tuesday, September 15, Impact BioMedical Inc.’s IBO share price has surged by 11.57%, which has investors questioning if this is right time to sell.Omar Beirat
Why Impact BioMedical Inc.’s (IBO) Stock Is Down 7.26%
As of Tuesday, September 08, Impact BioMedical Inc.’s IBO share price has dipped by 7.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Impact BioMedical Inc.’s (IBO) Stock Is Down 5.60%
As of Monday, August 24, Impact BioMedical Inc.’s IBO share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Impact BioMedical Inc.’s (IBO) Stock Is Down 6.52%
As of Tuesday, June 30, Impact BioMedical Inc.’s IBO share price has dipped by 6.52%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | IBO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $35.0 | $419.8 | 14% |
|
| Shares Out (Mil) | 8.5 | 43.5 | 19% |
|
| Institutional Ownership | 52.1% | 80.9% | 37% |
|
| Float (Mil) | 0.9 | 46.7 | 2% |
|
| Beta | 2.73 | 0.71 | 97% |
|
| Avg Daily Volume (000s) | 19 | 281 | 21% |
|
| Price Change (52-week) |
(39.0%) | 53.5% | 25% |
|
| Growth | IBO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (81.4%) | (1.8%) | 3% |
|
| EPS (5yr) | (113.9%) | 14.9% | 1 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (140.2%) | (15.1%) | 0% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IBO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $301 | na |
|
| Net Income (TTM) (Mil) | $1 | ($11) | 39% |
|
| EPS (TTM) | $0.126 | ($0.600) | 44% |
|
| Operating Cash Flow (TTM) (Mil) | ($1) | ($6) | 31% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $37 | $446 | 14% |
|
| Valuation | IBO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.25 | 2.01 | 71% |
|
| P/E | 62.1 | 21.4 | 90% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IBO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.7% | na |
|
| Net Margin | na | 3.6% | na |
|
| ROA | 4.4% | (22.2%) | 68% |
|
| ROE | 433.4% | (21.5%) | 99% |
|
| Liabilities to Assets | 16.3% | 31.5% | 10% |
|
| F-Score | 3 | 3 | 18% |
|
Impact BioMedical Inc. did not pass any screens on 11/6/2026.
